0

Close
 
Upcoming Allied Market Research
2023
Folliculotropic Mycosis Fungoides Treatment Market

Folliculotropic Mycosis Fungoides Treatment Market

by Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy), by Drug Type (Topical Steroids, Mechlorethamine, Interferons) and by Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Drug Store): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A13192
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Folliculotropic Mycosis Fungoides Treatment Market

Request Now !

Folliculotropic Mycosis Fungoides Treatment Market Overview 2030

Folliculotropic mycosis fungoides is a type of cutaneous T-cell lymphoma. This is a rare disease in which white blood cells (WBC) turn into cancerous cell due genetic mutation. This causes red patches on the skin without having any injury to the skin. Moreover, plaques, acneiform lesions, and tumor are some common symptoms of this disease. This disease is more common in males other than females. Treatments are based upon how severe is the disease condition in particular human. Treatments such as irradiation, photochemotherapy, ultra violet A, photodynamic therapy, and carbon dioxide laser surgery are used in the treatment of this disease.

COVID-19 Impact Analysis             

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the folliculotropic mycosis fungoides treatment market.

Top Impacting Factors

  • Rise in incidence of mycosis fungoides disease, surge in geriatric population, increase in cases of genetic disorders, surge in health conscious peoples, rise in patient suffering from weak immunity, and increase in number of lymphoma cancer cases across the world are the major factors that drive the growth of the folliculotropic mycosis fungoides treatment market.
  • In addition, increase in investment in research areas to develop effective treatment methods, surge in number of collaboration between hospital & labs for improvement in technology, rise in demand for targeted drug therapies, increase in launch of novel immunotherapy drugs in market, and surge in demand for effective cancer diagnosis procedures are some factors that fuel the growth of the folliculotropic mycosis fungoides treatment market.
  • However, side effects related use of treatment and high cost associated with treatment restrain the growth of the folliculotropic mycosis fungoides treatment market.
  • Contrarily, rise in cancer patient in developing & developed countries and strong R & D pipeline of novel products are expected to offer lucrative opportunities for the expansion of the market.

Market Trends

New Product Launches to Flourish the Market

In 2020, Kyowa Kirin Co. Ltd announced approval of European Commission for launch of POTELIGEO in Germany. This product is first class humanised monoclonal antibody that help in treatment of mycosis fungoides in adults.

In 2020, Takeda China announced launch of ADCETRIS. This product can be used in adult patient for treatment of folliculotropic mycosis fungoides in combination with chemotherapy.

Key Benefits of the Report

  • This study presents the analytical depiction of folliculotropic mycosis fungoides treatment market industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the folliculotropic mycosis fungoides treatment market share.
  • The current market is quantitatively analyzed to highlight the folliculotropic mycosis fungoides treatment market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Folliculotropic Mycosis Fungoides Treatment Market Report             

  • Which are the leading players active in the folliculotropic mycosis fungoides treatment market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What is "folliculotropic mycosis fungoides treatment"?
  • What is "folliculotropic mycosis fungoides treatment" market prediction in the future?
  • Who are the leading global players in the "folliculotropic mycosis fungoides treatment" market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "folliculotropic mycosis fungoides treatment" market report?

 Folliculotropic Mycosis Fungoides Treatment Market Report Highlights

Aspects Details
By Treatment
  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy
  • Targeted Therapy
By Drug Type
  • Topical Steroids
  • Mechlorethamine
  • Interferons
By Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Drug Store
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players GlaxoSmithKline Plc., Bayer AG, Novartis AG, Horizon Therapeutics plc., Pfizer Inc., Mallinckrodt Plc., Astellas Pharma Inc., Merck Co., Elorac, Azurity Pharmaceuticals Inc., Abbott, Seattle Genetics, Inc., Slogenix, Mylan, Eisai Co. Ltd.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET, BY TREATMENT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Treatment

    • 4.2. Chemotherapy

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Radiation Therapy

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Immunotherapy

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Targeted Therapy

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET, BY DRUG TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Drug Type

    • 5.2. Topical Steroids

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Mechlorethamine

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Interferons

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET, BY DISTRIBUTION CHANNEL

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Distribution Channel

    • 6.2. Hospital Pharmacy

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Online Pharmacy

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Retail Pharmacy

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Drug Store

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Treatment

      • 7.2.3. Market Size and Forecast, By Drug Type

      • 7.2.4. Market Size and Forecast, By Distribution Channel

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Folliculotropic Mycosis Fungoides Treatment Market

        • 7.2.6.1. Market Size and Forecast, By Treatment
        • 7.2.6.2. Market Size and Forecast, By Drug Type
        • 7.2.6.3. Market Size and Forecast, By Distribution Channel

      • 7.2.7. Canada Folliculotropic Mycosis Fungoides Treatment Market

        • 7.2.7.1. Market Size and Forecast, By Treatment
        • 7.2.7.2. Market Size and Forecast, By Drug Type
        • 7.2.7.3. Market Size and Forecast, By Distribution Channel

      • 7.2.8. Mexico Folliculotropic Mycosis Fungoides Treatment Market

        • 7.2.8.1. Market Size and Forecast, By Treatment
        • 7.2.8.2. Market Size and Forecast, By Drug Type
        • 7.2.8.3. Market Size and Forecast, By Distribution Channel

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Treatment

      • 7.3.3. Market Size and Forecast, By Drug Type

      • 7.3.4. Market Size and Forecast, By Distribution Channel

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Folliculotropic Mycosis Fungoides Treatment Market

        • 7.3.6.1. Market Size and Forecast, By Treatment
        • 7.3.6.2. Market Size and Forecast, By Drug Type
        • 7.3.6.3. Market Size and Forecast, By Distribution Channel

      • 7.3.7. Germany Folliculotropic Mycosis Fungoides Treatment Market

        • 7.3.7.1. Market Size and Forecast, By Treatment
        • 7.3.7.2. Market Size and Forecast, By Drug Type
        • 7.3.7.3. Market Size and Forecast, By Distribution Channel

      • 7.3.8. Italy Folliculotropic Mycosis Fungoides Treatment Market

        • 7.3.8.1. Market Size and Forecast, By Treatment
        • 7.3.8.2. Market Size and Forecast, By Drug Type
        • 7.3.8.3. Market Size and Forecast, By Distribution Channel

      • 7.3.9. Spain Folliculotropic Mycosis Fungoides Treatment Market

        • 7.3.9.1. Market Size and Forecast, By Treatment
        • 7.3.9.2. Market Size and Forecast, By Drug Type
        • 7.3.9.3. Market Size and Forecast, By Distribution Channel

      • 7.3.10. UK Folliculotropic Mycosis Fungoides Treatment Market

        • 7.3.10.1. Market Size and Forecast, By Treatment
        • 7.3.10.2. Market Size and Forecast, By Drug Type
        • 7.3.10.3. Market Size and Forecast, By Distribution Channel

      • 7.3.11. Russia Folliculotropic Mycosis Fungoides Treatment Market

        • 7.3.11.1. Market Size and Forecast, By Treatment
        • 7.3.11.2. Market Size and Forecast, By Drug Type
        • 7.3.11.3. Market Size and Forecast, By Distribution Channel

      • 7.3.12. Rest Of Europe Folliculotropic Mycosis Fungoides Treatment Market

        • 7.3.12.1. Market Size and Forecast, By Treatment
        • 7.3.12.2. Market Size and Forecast, By Drug Type
        • 7.3.12.3. Market Size and Forecast, By Distribution Channel

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Treatment

      • 7.4.3. Market Size and Forecast, By Drug Type

      • 7.4.4. Market Size and Forecast, By Distribution Channel

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Folliculotropic Mycosis Fungoides Treatment Market

        • 7.4.6.1. Market Size and Forecast, By Treatment
        • 7.4.6.2. Market Size and Forecast, By Drug Type
        • 7.4.6.3. Market Size and Forecast, By Distribution Channel

      • 7.4.7. Japan Folliculotropic Mycosis Fungoides Treatment Market

        • 7.4.7.1. Market Size and Forecast, By Treatment
        • 7.4.7.2. Market Size and Forecast, By Drug Type
        • 7.4.7.3. Market Size and Forecast, By Distribution Channel

      • 7.4.8. India Folliculotropic Mycosis Fungoides Treatment Market

        • 7.4.8.1. Market Size and Forecast, By Treatment
        • 7.4.8.2. Market Size and Forecast, By Drug Type
        • 7.4.8.3. Market Size and Forecast, By Distribution Channel

      • 7.4.9. South Korea Folliculotropic Mycosis Fungoides Treatment Market

        • 7.4.9.1. Market Size and Forecast, By Treatment
        • 7.4.9.2. Market Size and Forecast, By Drug Type
        • 7.4.9.3. Market Size and Forecast, By Distribution Channel

      • 7.4.10. Australia Folliculotropic Mycosis Fungoides Treatment Market

        • 7.4.10.1. Market Size and Forecast, By Treatment
        • 7.4.10.2. Market Size and Forecast, By Drug Type
        • 7.4.10.3. Market Size and Forecast, By Distribution Channel

      • 7.4.11. Thailand Folliculotropic Mycosis Fungoides Treatment Market

        • 7.4.11.1. Market Size and Forecast, By Treatment
        • 7.4.11.2. Market Size and Forecast, By Drug Type
        • 7.4.11.3. Market Size and Forecast, By Distribution Channel

      • 7.4.12. Malaysia Folliculotropic Mycosis Fungoides Treatment Market

        • 7.4.12.1. Market Size and Forecast, By Treatment
        • 7.4.12.2. Market Size and Forecast, By Drug Type
        • 7.4.12.3. Market Size and Forecast, By Distribution Channel

      • 7.4.13. Indonesia Folliculotropic Mycosis Fungoides Treatment Market

        • 7.4.13.1. Market Size and Forecast, By Treatment
        • 7.4.13.2. Market Size and Forecast, By Drug Type
        • 7.4.13.3. Market Size and Forecast, By Distribution Channel

      • 7.4.14. Rest of Asia Pacific Folliculotropic Mycosis Fungoides Treatment Market

        • 7.4.14.1. Market Size and Forecast, By Treatment
        • 7.4.14.2. Market Size and Forecast, By Drug Type
        • 7.4.14.3. Market Size and Forecast, By Distribution Channel

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Treatment

      • 7.5.3. Market Size and Forecast, By Drug Type

      • 7.5.4. Market Size and Forecast, By Distribution Channel

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Folliculotropic Mycosis Fungoides Treatment Market

        • 7.5.6.1. Market Size and Forecast, By Treatment
        • 7.5.6.2. Market Size and Forecast, By Drug Type
        • 7.5.6.3. Market Size and Forecast, By Distribution Channel

      • 7.5.7. South Africa Folliculotropic Mycosis Fungoides Treatment Market

        • 7.5.7.1. Market Size and Forecast, By Treatment
        • 7.5.7.2. Market Size and Forecast, By Drug Type
        • 7.5.7.3. Market Size and Forecast, By Distribution Channel

      • 7.5.8. Saudi Arabia Folliculotropic Mycosis Fungoides Treatment Market

        • 7.5.8.1. Market Size and Forecast, By Treatment
        • 7.5.8.2. Market Size and Forecast, By Drug Type
        • 7.5.8.3. Market Size and Forecast, By Distribution Channel

      • 7.5.9. UAE Folliculotropic Mycosis Fungoides Treatment Market

        • 7.5.9.1. Market Size and Forecast, By Treatment
        • 7.5.9.2. Market Size and Forecast, By Drug Type
        • 7.5.9.3. Market Size and Forecast, By Distribution Channel

      • 7.5.10. Argentina Folliculotropic Mycosis Fungoides Treatment Market

        • 7.5.10.1. Market Size and Forecast, By Treatment
        • 7.5.10.2. Market Size and Forecast, By Drug Type
        • 7.5.10.3. Market Size and Forecast, By Distribution Channel

      • 7.5.11. Rest of LAMEA Folliculotropic Mycosis Fungoides Treatment Market

        • 7.5.11.1. Market Size and Forecast, By Treatment
        • 7.5.11.2. Market Size and Forecast, By Drug Type
        • 7.5.11.3. Market Size and Forecast, By Distribution Channel

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Astellas Pharma Inc.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Bayer AG

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Novartis AG

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Pfizer Inc.

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Merck Co.

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. GlaxoSmithKline Plc.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Abbott

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Mylan

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Mallinckrodt Plc.

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Eisai Co. Ltd.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

    • 9.11. Azurity Pharmaceuticals Inc.

      • 9.11.1. Company Overview

      • 9.11.2. Key Executives

      • 9.11.3. Company Snapshot

      • 9.11.4. Operating Business Segments

      • 9.11.5. Product Portfolio

      • 9.11.6. Business Performance

      • 9.11.7. Key Strategic Moves and Developments

    • 9.12. Elorac

      • 9.12.1. Company Overview

      • 9.12.2. Key Executives

      • 9.12.3. Company Snapshot

      • 9.12.4. Operating Business Segments

      • 9.12.5. Product Portfolio

      • 9.12.6. Business Performance

      • 9.12.7. Key Strategic Moves and Developments

    • 9.13. Slogenix

      • 9.13.1. Company Overview

      • 9.13.2. Key Executives

      • 9.13.3. Company Snapshot

      • 9.13.4. Operating Business Segments

      • 9.13.5. Product Portfolio

      • 9.13.6. Business Performance

      • 9.13.7. Key Strategic Moves and Developments

    • 9.14. Seattle Genetics, Inc.

      • 9.14.1. Company Overview

      • 9.14.2. Key Executives

      • 9.14.3. Company Snapshot

      • 9.14.4. Operating Business Segments

      • 9.14.5. Product Portfolio

      • 9.14.6. Business Performance

      • 9.14.7. Key Strategic Moves and Developments

    • 9.15. Horizon Therapeutics Plc.

      • 9.15.1. Company Overview

      • 9.15.2. Key Executives

      • 9.15.3. Company Snapshot

      • 9.15.4. Operating Business Segments

      • 9.15.5. Product Portfolio

      • 9.15.6. Business Performance

      • 9.15.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET FOR CHEMOTHERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET FOR RADIATION THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET FOR IMMUNOTHERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET FOR TARGETED THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET FOR TOPICAL STEROIDS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET FOR MECHLORETHAMINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET FOR INTERFERONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET FOR DRUG STORE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 20. U.S. FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 21. U.S. FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 22. U.S. FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 23. CANADA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 24. CANADA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 25. CANADA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. FRANCE FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 36. GERMANY FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 37. GERMANY FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 38. GERMANY FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 39. ITALY FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 40. ITALY FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 41. ITALY FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 45. UK FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 46. UK FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 47. UK FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 48. RUSSIA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 49. RUSSIA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 50. RUSSIA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 51. REST OF EUROPE FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 52. REST OF EUROPE FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 53. REST OF EUROPE FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 56. ASIA-PACIFIC FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 57. ASIA-PACIFIC FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. CHINA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 59. CHINA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 60. CHINA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 61. JAPAN FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 62. JAPAN FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 63. JAPAN FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 64. INDIA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 65. INDIA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 66. INDIA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. AUSTRALIA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 71. AUSTRALIA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 72. AUSTRALIA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 73. THAILAND FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 74. THAILAND FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 75. THAILAND FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 76. MALAYSIA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 77. MALAYSIA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 78. MALAYSIA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 79. INDONESIA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 80. INDONESIA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 81. INDONESIA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 85. LAMEA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 86. LAMEA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 87. LAMEA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 88. LAMEA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 89. BRAZIL FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 90. BRAZIL FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 91. BRAZIL FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 92. SOUTH AFRICA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 93. SOUTH AFRICA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH AFRICA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 95. SAUDI ARABIA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 96. SAUDI ARABIA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 97. SAUDI ARABIA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 98. UAE FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 99. UAE FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 100. UAE FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 101. ARGENTINA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 102. ARGENTINA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 103. ARGENTINA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 104. REST OF LAMEA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 105. REST OF LAMEA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 106. REST OF LAMEA FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 107. ASTELLAS PHARMA INC.: KEY EXECUTIVES
  • TABLE 108. ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
  • TABLE 109. ASTELLAS PHARMA INC.: OPERATING SEGMENTS
  • TABLE 110. ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO
  • TABLE 111. ASTELLAS PHARMA INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. BAYER AG: KEY EXECUTIVES
  • TABLE 113. BAYER AG: COMPANY SNAPSHOT
  • TABLE 114. BAYER AG: OPERATING SEGMENTS
  • TABLE 115. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 116. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 118. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 119. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 120. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 121. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. PFIZER INC.: KEY EXECUTIVES
  • TABLE 123. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 124. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 125. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 126. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 127. MERCK CO.: KEY EXECUTIVES
  • TABLE 128. MERCK CO.: COMPANY SNAPSHOT
  • TABLE 129. MERCK CO.: OPERATING SEGMENTS
  • TABLE 130. MERCK CO.: PRODUCT PORTFOLIO
  • TABLE 131. MERCK CO.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 132. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
  • TABLE 133. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
  • TABLE 134. GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
  • TABLE 135. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
  • TABLE 136. GLAXOSMITHKLINE PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 137. ABBOTT: KEY EXECUTIVES
  • TABLE 138. ABBOTT: COMPANY SNAPSHOT
  • TABLE 139. ABBOTT: OPERATING SEGMENTS
  • TABLE 140. ABBOTT: PRODUCT PORTFOLIO
  • TABLE 141. ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 142. MYLAN: KEY EXECUTIVES
  • TABLE 143. MYLAN: COMPANY SNAPSHOT
  • TABLE 144. MYLAN: OPERATING SEGMENTS
  • TABLE 145. MYLAN: PRODUCT PORTFOLIO
  • TABLE 146. MYLAN: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. MALLINCKRODT PLC.: KEY EXECUTIVES
  • TABLE 148. MALLINCKRODT PLC.: COMPANY SNAPSHOT
  • TABLE 149. MALLINCKRODT PLC.: OPERATING SEGMENTS
  • TABLE 150. MALLINCKRODT PLC.: PRODUCT PORTFOLIO
  • TABLE 151. MALLINCKRODT PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. EISAI CO. LTD.: KEY EXECUTIVES
  • TABLE 153. EISAI CO. LTD.: COMPANY SNAPSHOT
  • TABLE 154. EISAI CO. LTD.: OPERATING SEGMENTS
  • TABLE 155. EISAI CO. LTD.: PRODUCT PORTFOLIO
  • TABLE 156. EISAI CO. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 157. AZURITY PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 158. AZURITY PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 159. AZURITY PHARMACEUTICALS INC.: OPERATING SEGMENTS
  • TABLE 160. AZURITY PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 161. AZURITY PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 162. ELORAC: KEY EXECUTIVES
  • TABLE 163. ELORAC: COMPANY SNAPSHOT
  • TABLE 164. ELORAC: OPERATING SEGMENTS
  • TABLE 165. ELORAC: PRODUCT PORTFOLIO
  • TABLE 166. ELORAC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 167. SLOGENIX: KEY EXECUTIVES
  • TABLE 168. SLOGENIX: COMPANY SNAPSHOT
  • TABLE 169. SLOGENIX: OPERATING SEGMENTS
  • TABLE 170. SLOGENIX: PRODUCT PORTFOLIO
  • TABLE 171. SLOGENIX: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 172. SEATTLE GENETICS, INC.: KEY EXECUTIVES
  • TABLE 173. SEATTLE GENETICS, INC.: COMPANY SNAPSHOT
  • TABLE 174. SEATTLE GENETICS, INC.: OPERATING SEGMENTS
  • TABLE 175. SEATTLE GENETICS, INC.: PRODUCT PORTFOLIO
  • TABLE 176. SEATTLE GENETICS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 177. HORIZON THERAPEUTICS PLC.: KEY EXECUTIVES
  • TABLE 178. HORIZON THERAPEUTICS PLC.: COMPANY SNAPSHOT
  • TABLE 179. HORIZON THERAPEUTICS PLC.: OPERATING SEGMENTS
  • TABLE 180. HORIZON THERAPEUTICS PLC.: PRODUCT PORTFOLIO
  • TABLE 181. HORIZON THERAPEUTICS PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET SEGMENTATION
  • FIGURE 2. GLOBAL FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET
  • FIGURE 3. SEGMENTATION FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALFOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET
  • FIGURE 11. FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET SEGMENTATION, BY BY TREATMENT
  • FIGURE 12. FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET FOR RADIATION THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET FOR IMMUNOTHERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET FOR TARGETED THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET SEGMENTATION, BY BY DRUG TYPE
  • FIGURE 17. FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET FOR TOPICAL STEROIDS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET FOR MECHLORETHAMINE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET FOR INTERFERONS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 21. FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET FOR DRUG STORE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 26. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 27. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 28. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 29. COMPETITIVE DASHBOARD
  • FIGURE 30. COMPETITIVE HEATMAP: FOLLICULOTROPIC MYCOSIS FUNGOIDES TREATMENT MARKET
  • FIGURE 31. Top player positioning, 2022
  • FIGURE 32. ASTELLAS PHARMA INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 33. ASTELLAS PHARMA INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 34. ASTELLAS PHARMA INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 35. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. BAYER AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. BAYER AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. MERCK CO.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. MERCK CO.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. MERCK CO.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. GLAXOSMITHKLINE PLC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. ABBOTT: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. ABBOTT: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. ABBOTT: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 53. MYLAN: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. MYLAN: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 55. MYLAN: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 56. MALLINCKRODT PLC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. MALLINCKRODT PLC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 58. MALLINCKRODT PLC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 59. EISAI CO. LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. EISAI CO. LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 61. EISAI CO. LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 62. AZURITY PHARMACEUTICALS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 63. AZURITY PHARMACEUTICALS INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 64. AZURITY PHARMACEUTICALS INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 65. ELORAC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 66. ELORAC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 67. ELORAC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 68. SLOGENIX: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 69. SLOGENIX: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 70. SLOGENIX: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 71. SEATTLE GENETICS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 72. SEATTLE GENETICS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 73. SEATTLE GENETICS, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 74. HORIZON THERAPEUTICS PLC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 75. HORIZON THERAPEUTICS PLC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 76. HORIZON THERAPEUTICS PLC.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Folliculotropic Mycosis Fungoides Treatment Market

Start reading.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers